Organogenesis Holdings stock falls 2.13 percent as Q2 revenue drops sharply

Published on 09/28/2026 at 23:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ORGO stock carries a USD 1.38 quote on Nasdaq dated September 28, 2026. Q2 revenue was USD 42.8 million versus USD 100.8 million a year earlier.

ORGO, US68620V1026, Illustration mit AI erstellt.

Organogenesis Holdings stock (ISIN US68620V1026) was last at USD 1.38 on Nasdaq at 4:00 p.m. ET on September 28, 2026, down 2.13 percent from USD 1.41. The move comes as the regenerative medicine company works through a sharp revenue reset tied to its wound care business.

Revenue drops 58 percent

Stock Titan reported that Organogenesis generated second-quarter 2026 net product revenue of USD 42.8 million for the period ended June 30, 2026, compared with USD 100.8 million a year earlier. That was a 58.00 percent decline, while Advanced Wound Care revenue fell 61.00 percent to USD 36.1 million.

The same filing summary showed a net loss of USD 96.3 million, or USD -0.77 per share, and an adjusted net loss of USD 89.0 million. MarketBeat said adjusted EPS missed the USD -0.35 consensus estimate by USD 0.36, while revenue missed the USD 54.27 million consensus estimate by USD 10.51 million.

Guidance resets the baseline

Organogenesis updated its 2026 total net revenue guidance to USD 179.0 million to USD 215.0 million, a projected 62.00 percent to 68.00 percent decline from USD 564.2 million in 2025, according to Stock Titan. The range gives investors a clearer measure of the reimbursement pressure affecting advanced wound care products.

On August 7, 2026, Truist Financial reduced its price target from USD 3.00 to USD 2.00 and maintained a Hold rating, MarketBeat reported. The USD 2.00 target lies 44.93 percent above the September 28 price, although the target itself reflects a cautious reassessment of near-term earnings.

Small valuation, large range

Organogenesis had a market capitalization of USD 177.6 million and volume of 420,117 shares on September 28, 2026. Its session range was USD 1.35 to USD 1.39, while the 52-week range was USD 1.34 to USD 7.08.

The company develops therapies for advanced wound management, surgical repair and sports medicine. ToAlpha lists November 5, 2026 as the next earnings date, making the third-quarter update the next scheduled test of the revised revenue outlook.

ORGO stock remains under pressure

Organogenesis Holdings stock combines a USD 177.6 million market capitalization with a 58.00 percent quarterly revenue decline and a 62.00 percent to 68.00 percent full-year guidance reduction. The next earnings date on November 5, 2026 will show whether the second-half forecast is tracking the company plan.